sleep disorders

News

Alkermes breaks new ground in narcolepsy with orexin drug

Alkermes' alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.

News

Court sides with Vanda over FDA's Hetlioz rejection

A court has ordered the FDA to revisit a decision to turn down a drug for jet lag developed by Vanda, potentially setting a crucial legal precedent.

News

Algorithm spots common sleep disorder linked to dementia

An AI algorithm can help detect REM sleep behaviour disorder, which affects millions of people and is a warning signal for neurological diseases.

Digital

How measurement technology can advance sleep monitoring in c...

As of 2024, more than one-third of American adults don't get enough sleep, and sleep satisfaction levels are worryingly low.

Alkermes breaks new ground in narcolepsy with orexin drug

Court sides with Vanda over FDA's Hetlioz rejection

Algorithm spots common sleep disorder linked to dementia

How measurement technology can advance sleep monitoring in c...

GSK to quit Stevenage for new R&D site in Cambridge

Discover a new era of healthcare panel engagement: Grounded ...

sleep disorders

Editor's Picks